Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
This series of 16 video interviews was recorded at the annual symposium of the Prostate Cancer Research Institute in Los Angeles, California, in September 2009. It includes interviews with 9 physicians and 6 patient advocates, and is now available on the Prostate Cancer International web site as well as on YouTube.
Filed under: Uncategorized | Comments Off
Today’s news reports address: Statins and prostate cancer prevention 10-year results of low-dose brachytherapy in a Spanish patient cohort Selective nuclear androgen receptor exporters (SNAREs)
Filed under: Uncategorized | Tagged: 10-year survival, prevention. brachytherapy, selective nuclear androgen receptor exporters, SNARE, statins | Leave a Comment »
Guidelines suggest that the optimal management of patients with castration-resistant prostate cancer (CRPC) — also known as hormone-refractory prostate cancer or HRPC — is participation in a randomized clinical trial. But encouraging community-based clinicians to enroll their patients in clinical trials has long been problematic.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: clinical trials, CRPC, eligibility | 1 Comment »
The news reports today cover studies on: Initial PSA levels and risk for prostate cancer in black and in white Americans 3 T MR imaging, MRI-guided biopsies, and identification of sites of local recurrence after first-line EBRT pT0 disease in men with biopsy-detected prostate cancer Outcomes of immediate surgery compared to deferred treatment
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: defferred, immediate, MRI-guided biopsy, PSA level, pT0 disease, race, risk, surgery, Treatment | 7 Comments »
In today’s new reports we summarize information from recent papers dealing with: Apical biopsy cores in initial diagnosis of prostate cancer Imaging studies in the initial work-up of newly diagnosed patients Intrafascial dissection of peri-prostatic tissue during laparoscopic surgery Similarity of short-term rates of biochemical recurrence after open surgery or RALP Does how we define [...]
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: apex, biochemical recurrence, biopsy, Diagnosis, dissection, imaging, intrafascial, open, RALP, risk, robot-assisted, surgery, work-up | 1 Comment »
A new report from members of the Transatlantic Prostate Study Group has suggested that information about three specific genes may be sufficient to identify a high proportion of men with potentially lethal as opposed to indolent prostate cancer.
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: ERG/ETV1, gene loss, gene rearrangement, prognosis, PTEN, survival | 5 Comments »
According to a story on ScienceDaily today, investigators are continuing to plan for a Phase III clinical trial of PROSTVAC-VF — a poxvirus-based prostate cancer “vaccine” — in men with castration-resistant prostate cancer (CRPC).
Filed under: Drugs in development | Tagged: castration-resistant prostate cancer, CRPC, immunobiologics, PROSTVAC-VF, vaccine | 14 Comments »
It has long been known that patient outcomes and complications after prostate surgery vary among surgeons to a greater extent than may be accounted for by chance.
Filed under: Management, Treatment | Tagged: heterogeneity, outcomes, radical prostatectomy | 6 Comments »
A study of prostate cancer treatments provided to economically disadvantaged men with relatively advanced forms of prostate cancer (compared to the average in the US today) suggests that where they were treated had at least as much (and probably more) impact on their treatment as their actual clinical condition.
Filed under: Management, Treatment | Tagged: disadvantaged patients, economics, IMPACT | Leave a Comment »
In this weekend’s prostate cancer news reports, we have addressed recent publications on: A SNP that may be specifically linked to risk for prostate cancer in African Americans The need for extended biopsies in men with larger prostates who are considering focal treatment for prostate cancer A possible association between diabetes, race, obesity, and risk [...]
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: African American, age, biopsy, brachytherapy, diabetes, focal, hormone therapy, mortality, neoadjuvant, obesity, race, single nucleotide polymorphism, SNP, Treatment | Leave a Comment »
According to an e-mail from our friends at Us TOO the AFFIRM trial (A study evaluating the eFFicacy and safety of Investigational dRug MDV3100 in men with advanced prostate cancer) has started to enroll patients in the USA. It had started to enroll patients in Europe earlier this month.
Filed under: Drugs in development | Tagged: AFFIRM, MDV3100, Phase III, trial | 5 Comments »
We want to again make the point that treatment of localized prostate cancer with high-intensity focused ultrasound (HIFU), in the hands of inexperienced clinicians, is not necessarily as safe as some of the sales pitches might suggest. In the hands of highly experienced or highly trained HIFU practioners, with access to second- and third-generation equipment, [...]
Filed under: Management, Treatment | Tagged: complications, HIFU, high-intensity focused ultrasound | 2 Comments »
A newly published Italian study offers what we believe to be the first direct comparison of two “modern” types of external beam radiation therapy for the treatment of localized, high-risk prostate cancer. This is a relatively small trial, with relatively brief follow-up to date, but the results are nontheless interesting and important.
Filed under: Management, Treatment | Tagged: "high risk", external beam radiation, localized, randomized, trial | 2 Comments »
The American Society for Clinical Oncology has recently updated its guidelines on genetic and genomic testing for susceptibility to cancer. The entire guideline is available on line for any interested reader.
Filed under: Diagnosis, Risk | Tagged: genetic, guideline, susceptibility, testing | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site